Clinical Trial Update: Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating capecitabine, gemcitabine, and bevacizumab in sarcomatoid renal cell carcinoma has completed and posted results in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma
• Sarcomatoid Renal Cell Carcinoma

Drugs mentioned

• Avastin (bevacizumab)
• Gemzar (gemcitabine)
• Xeloda (capecitabine)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Renal Cell Carcinoma, Kidney Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-06-22